Who are Thymosin alpha1 & Pegylated Interferon-alpha2a's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): histamine dihydrochloride and IL-2, Acetazolamide Levamisole.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/thymosin-alpha1-pegylated-interferon-alpha2a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Thymosin alpha1 & Pegylated Interferon-alpha2a — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Thymosin alpha1 & Pegylated Interferon-alpha2a (Thymosin alpha1 & Pegylated Interferon-alpha2a) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator combination. Area: Immunology, Oncology, Infectious Disease.

marketed Immunomodulator combination T-cell maturation pathway; interferon-alpha receptor (IFNAR) Immunology, Oncology, Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Thymosin alpha1 & Pegylated Interferon-alpha2a (Thymosin alpha1 & Pegylated Interferon-alpha2a) — Seoul National University Hospital. This combination enhances immune response by stimulating T-cell maturation and proliferation (thymosin alpha1) while amplifying interferon-mediated antiviral and anti-tumor effects (pegylated interferon-alpha2a).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Thymosin alpha1 & Pegylated Interferon-alpha2a TARGET	Thymosin alpha1 & Pegylated Interferon-alpha2a	Seoul National University Hospital	marketed	Immunomodulator combination	T-cell maturation pathway; interferon-alpha receptor (IFNAR)
histamine dihydrochloride and IL-2	histamine dihydrochloride and IL-2	Cytovia, Inc.	marketed	Immunomodulator combination	Histamine receptors (H1, H2, H3, H4) and IL-2 receptor
Acetazolamide Levamisole	Acetazolamide Levamisole	The First Affiliated Hospital of Zhengzhou University	phase 3	Carbonic anhydrase inhibitor + immunomodulator combination	Carbonic anhydrase II (acetazolamide component); levamisole target unclear in this context

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator combination class)

Cytovia, Inc. · 1 drug in this class
Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Thymosin alpha1 & Pegylated Interferon-alpha2a — Competitive Intelligence Brief. https://druglandscape.com/ci/thymosin-alpha1-pegylated-interferon-alpha2a. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab